Christopher Easterling, MD
Family Medicine · Graham, TXNPI 1538554134
Payments from drug & device makers
Across 253 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$476
- AstraZeneca$427
- Novo Nordisk$396
- Lilly USA, LLC$362
- Pfizer$299
- Amgen$295
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,105100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $476 |
| AstraZeneca | 26 | $427 |
| Novo Nordisk | 29 | $396 |
| Lilly USA, LLC | 23 | $362 |
| Pfizer | 18 | $299 |
| Amgen | 23 | $295 |
| Astellas Pharma US Inc | 14 | $290 |
| AbbVie(2 entities) | 13 | $283 |
| GSK | 16 | $276 |
| Boehringer Ingelheim | 10 | $183 |
| Bayer | 6 | $98 |
| Exact Sciences | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Johnson & Johnson | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 4 | $50 |
| Mylan Specialty L.p. | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Merck | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Abbott | 2 | $27 |
| Lundbeck LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $11 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$4,111 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $126,249 |
| EliquisApixaban | 105 | $92,180 |
| FarxigaDapagliflozin Propanediol | 74 | $58,979 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $40,797 |
| XareltoRivaroxaban | 23 | $26,588 |
| LinzessLinaclotide | 22 | $26,054 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 115 | $25,762 |
| JardianceEmpagliflozin | 26 | $24,511 |
| MounjaroTirzepatide | 20 | $20,731 |
| EntrestoSacubitril/Valsartan | 32 | $19,602 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $18,385 |
| ProliaDenosumab | 11 | $18,000 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $17,560 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 42 | $13,519 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $396 | $126,249106 claims |
| PfizerEliquis, Abrysvo, Premarin | $299 | $110,991162 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $276 | $83,764212 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $427 | $76,53994 claims |
| AbbVieLinzess, Synthroid | $283 | $31,19194 claims |
| Johnson & JohnsonXarelto | $56 | $26,58823 claims |
| Boehringer IngelheimJardiance | $183 | $24,51126 claims |
| Lilly USA, LLCMounjaro | $362 | $20,73120 claims |
| MerckJanumet Xr, Januvia, Belsomra | $29 | $20,42461 claims |
| NovartisEntresto | $476 | $19,60232 claims |
| AmgenProlia | $295 | $18,00011 claims |
| Astellas Pharma US IncMyrbetriq | $290 | $11,91413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Graham
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.